ClinicalTrials.gg
CompletedNCT06467201Updated Feb 19, 2026

SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females

A Phase 1 interventional study of KSHN001126 150mg and KSHN001126 300mg in Healthy Postmenopausal Women, sponsored by Amneal Pharmaceuticals, LLC. Completed at 2 sites in 2 countries. Open to female participants aged 45 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Amneal Pharmaceuticals, LLC · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
45 Years to 60 Years
Sex
Female
01

Study summary

This is an Open-label, Sequential dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of KSHN001126 in Healthy Human Post-Menopausal Female Volunteers. The primary objective of the study is to evaluate the safety and tolerability of increasing single doses of KSHN001126 while the secondary objective is to evaluate the plasma PK profile of KSHN001126 and its metabolites (KSHN001167, KSHN001168 and Fulvestrant) following ascending single oral doses of KSHN001126.

02

Conditions studied

  • Healthy Postmenopausal Women
03

In context

Lead sponsor

Amneal Pharmaceuticals, LLC is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written and communicate with the investigator and comprehend study-related procedures.
  2. Healthy, females aged 45 to 60 years old (inclusive), as determined by medical history and physical examination.
  3. at screening between 18 and 30 kg/m2, inclusive.
  4. Post-menopausal females (Menopause is defined as the female is either 12 months off menstrual period after the age of 50 years, or 12 months off menstrual period after the age of 40 years and Follicle Stimulating Hormone (FSH) > 40 mIU/mL. Amenorrhea should not be due to lactation).
  5. In good general health with no illness seen on physical examination or ongoing medical history, as determined by the Investigator.
  6. Documented 12-lead with no clinically significant abnormalities (with between 360 to 440 msec), as determined by the Investigator in screening or Day 0.
  7. No clinically significant abnormalities in screening or Day 0 laboratory tests, as determined by the Investigator ( should be ≥ 90 mL/min and Blood Urea Nitrogen / / ALT / Alkaline phosphatase / Total and direct should be \< ).
  8. Female participants must have a negative serum pregnancy (β-HCG) test at screening and a negative urine pregnancy test at Day 0 prior to dosing. Female participants must also be non-lactating.
  9. The participant is available to volunteer for the entire study duration and is willing to adhere to all protocol requirements.
  10. The participant has vital signs at screening, and at check-in within the following ranges:

    • Blood Pressure:

      • Systolic: (100- 140 mmHg
      • Diastolic: (60-90) mmHg
    • Body Temperature: (36.1 - 37.8) ºC, Pulse rate: 60 to 100 b/m. Respiratory rate: 12 to 20 bpm
  11. Participants with normal findings as determined by gynecological examination and USG Pelvis.
  12. With a normal or clinically acceptable mammogram
  13. With a normal or clinically acceptable PAP smear test
  14. Have a normal chest X-ray (P. A. view).
  15. Participant negative for -surface antigen, and (HIV)
  16. Participants who are generally healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring
  17. Adequate venous access and can able to give required blood samples.

Exclusion criteria

Exclusion Criteria:

  1. The participant is surgically induced female.
  2. Pregnant or lactating female participant.
  3. Any history of cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, chronic hepatic disease or any other disease which in the judgment of the Investigator would interfere with the study or confound the study results.
  4. History of allergy or major allergic reaction considered to be clinically significant by the Investigator.
  5. Receiving or has received any drug within the 30 days before receiving KSHN001126.
  6. History or presence of low count, bleeding issues or family history of bleeding disorders.
  7. Participant has a history of to heparin as checked at screening.
  8. The participant has known allergy to the drug under investigation, or to any ingredient in the preparation
  9. The participant has an evidence of antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of the consent to participation in the study or limit the ability to comply with the protocol requirements.
  10. Donated blood within 60 days of screening or otherwise experienced blood loss of >250 mL within the same period.
  11. Intending to begin new concomitant drug therapy or over-the-counter medication anytime from screening to the time of administration of study drug.
  12. Received or intending to receive a vaccination in the two weeks prior to dosing, or anytime during study participation.
  13. Received treatment with a drug that has not received regulatory approval for an indication during the 60 days preceding study enrollment.
  14. History of drug and/or alcohol dependence within past 12 months, and/or positive results on drug of abuse or alcohol tests.
  15. The participant is a smoker (smoker is defined as reporting tobacco use in the previous 3 months and/or has urine cotinine level equal or more than 500 ng/ml)
  16. Has taken any regular, prescribed, or over-the-counter medication with the exception of acetaminophen (maximum 2 g/day) or multi- vitamins in the 2 weeks prior to dosing (other medication may only be taken with the specific approval of the Investigator in consultation with the Medical Monitor).
  17. The participant with history of consuming alcohol or caffeine or related xanthine containing foods or beverages such as caffeine in tea, coffee, chocolates, cola and pepsi for 48 hours prior to dosing.
  18. The participant has consumed grapefruit-containing beverages and foods 7 days prior to dosing.
  19. within the last 5 years, with the exception of successfully treated basal cell carcinoma and carcinoma in situ uteri.
  20. The participant has prior history of hormonal replacement therapy.
  21. The participant has any estrogen- dependent conditions including breast cancer.
  22. Any condition that, in the opinion of the investigator, might interfere with study objectives.
  23. The participant has a history of osteoporosis or any disease affecting bone or metabolism.
  24. Intolerance to/ fear of venipuncture, needles, or blood draws
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    KSHN001126 150mg

    Low Dose

    Drug: KSHN001126 150mg

  • Experimental
    KSHN001126 300mg

    Mid Dose

    Drug: KSHN001126 300mg

  • Experimental
    KSHN001126 600mg

    High Dose

    Drug: KSHN001126 600mg

Interventions

  • DrugKSHN001126 150mg

    6 subjects will receive single oral dose of 150mg

  • DrugKSHN001126 300mg

    6 subjects will receive single oral dose of 300mg

  • DrugKSHN001126 600mg

    6 subjects will receive single oral dose of 600mg

06

What researchers measure

Primary outcomes

  1. Type, incidence, severity, seriousness, and relatedness of Adverse Events (AEs)

    Adverse events reported after dosing will be evaluated

    Time frame: Upto Day 15 after dosing

  2. Number of participants with abnormal laboratory tests results

    Laboratory abnormalities after dosing will be evaluated

    Time frame: Upto Day 15 after dosing

  3. Number of participants with abnormal vital signs

    Time frame: Upto Day 15 after dosing

  4. Number of participants with abnormal Electrocardiogram readings

    Impact on QTc interval will be evaluated

    Time frame: Upto Day 15 after dosing

Secondary outcomes

  1. Evaluate the Peak Plasma Concentration (Cmax) of KSHN001126 and its metabolites (KSHN001167, KSHN001168 and Fulvestrant) following ascending single oral doses of KSHN001126

    Time frame: 72 hours after dosing

  2. Evaluate the Area under the plasma concentration versus time curve (AUC) of KSHN001126 and its metabolites (KSHN001167, KSHN001168 and Fulvestrant) following ascending single oral doses of KSHN001126

    Time frame: 72 hours after dosing

  3. Evaluate the Time to maximum concentration (Tmax) of KSHN001126 and its metabolites (KSHN001167, KSHN001168 and Fulvestrant) following ascending single oral doses of KSHN001126

    Time frame: 72 hours after dosing

  4. Evaluate the half life (T1/2) of KSHN001126 and its metabolites (KSHN001167, KSHN001168 and Fulvestrant) following ascending single oral doses of KSHN001126

    Time frame: 72 hours after dosing

07

Study locations

2 sites
  • Advanced Pharma CR
    Miami, Florida 33147, United States
  • Health1 Superspeciality Hospital
    Ahmedabad, Gujarat 380058, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Dec 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2024
First posted
Jun 20, 2024
StartActual
Jun 3, 2024
Primary completionActual
Dec 8, 2024
CompletionActual
Mar 12, 2025
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06467201
Responsible party
Sponsor
First posted
Jun 20, 2024
Start date
Jun 3, 2024
Primary completion
Dec 8, 2024
Completion
Mar 12, 2025
Last update
Feb 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion